RESUMO
We aimed to evaluate the feasibility of a tailored physical activity (PA) prescription in overweight and obese people in a tertiary hospital in Lima, Peru. A feasibility pre-post-pilot study was conducted using mixed methods. Participants received a tailored prescription scheme for PA that lasted twelve weeks. It included two prescription sessions, three follow-up phone calls, and three evaluations. Primary feasibility outcomes were recruitment, visits, and phone call adherence. Primary intervention outcomes were self-reported PA levels and the 6 min walk test. Out of 228 people invited to participate, 30 were enrolled and received the first session of prescription, 11 went to the second session, and 21 went to the final evaluation; phone call participation decreased progressively during follow-up. There were no differences in the 6th week and the 12th week compared to the baseline for all the measures, except in the 6 min walk test. The participants considered the intervention was well designed, but they suggested complementing it with dietary instructions. The prescription of PA in overweight and obese people is feasible for promoting PA, but its implementation requires refinements to anticipate possible barriers to changing behavior.
Assuntos
Obesidade , Sobrepeso , Exercício Físico , Estudos de Viabilidade , Hospitais Públicos , Humanos , Projetos Piloto , PrescriçõesRESUMO
INTRODUCTION: We explore the limitations to adherence of hand-washing and evaluate the impact of a mHealth intervention for hand hygiene in residents. METHODOLOGY: We explore resident's perspectives about Hospital-acquired infections (HAI) and hand washing. In baseline, participants completed socio-demographic characteristics and hand-washing habits survey. The intervention consisted of sending SMS three times a week for two months about hand hygiene and "five moments" for hand washing. The cultures of hands and cell phones were analyzed at baseline, 2 months and 4 months. We used chi-square and adjusted Generalized Estimating Equations. RESULTS: Five physicians were interviewed and 33 participants were included for quantitative analysis. Critical barriers that hinder hand washing were identified. The proportion of Staphylococcus aureus in hands was 54.5% at baseline and was significantly reduced at 2 months follow-up (p = 0.009), but, benefit was lost when the intervention was discontinued; Escherichia coli and Klebsiella sp. were observed in 22.2% of hands, no changes were noted with intervention. In cell phones, there was a tendency to lower values of bacterial colonization after intervention for Staphylococcus aureus growth. CONCLUSIONS: High prevalence of contamination in hands and phones in medical residents were found. Serious barriers to compliance with hand washing must be overcome. It is possible that prolonged or continuous interventions could be necessary to optimize hand washing and reduce hand and cell phones contamination.
Assuntos
Telefone Celular , Desinfecção das Mãos , Promoção da Saúde/organização & administração , Internato e Residência , Adulto , Infecção Hospitalar/epidemiologia , Escherichia coli/isolamento & purificação , Feminino , Hospitais Públicos , Humanos , Klebsiella/isolamento & purificação , Masculino , Peru , Prevalência , Staphylococcus aureus/isolamento & purificação , Inquéritos e QuestionáriosRESUMO
BACKGROUND: COVID-19 can be asymptomatic in a substantial proportion of patients. The assessment and management of these patients constitute a key element to stop dissemination. AIM: To describe the assessment and treatment of asymptomatic infection in patients with a confirmed diagnosis of COVID-19. METHODS: We searched five databases and search engines for preprints/preproofs, up to August 22, 2020. We included cohort, cross-sectional, and case series studies, reporting the assessment and management of asymptomatic individuals. We extracted data on total discharges with negative PCR, length of hospitalization, treatment, and number of patients who remained asymptomatic. A random-effects model with inverse variance method was used to calculate the pooled prevalence. RESULTS: 41 studies (nine cross-sectional studies, five retrospective studies and 27 reports/case series; 647 asymptomatic individuals), were included, of which 47% were male (233/501). The age of patients was between 1month and 73 years. In patients who became symptomatic, length of hospitalization mean was 13.6 days (SD 6.4). Studies used lopinavir/ritonavir, hydroxychloroquine plus ritonavir/lopinavir, hydroxychloroquine with and without azithromycin, ribavirin plus interferon and interferon alfa. The proportion of individuals who remained asymptomatic was 91% (463/588 patients; 95%CI: 78.3%-98.7%); and asymptomatic individuals discharged with negative PCR was 86% (102/124 individuals; 95%CI: 58.4%-100%). CONCLUSIONS: There is no standard treatment for asymptomatic COVID-19 individuals. There are no studies of adequate design to make this decision. It has been shown that most asymptomatic individuals who were followed have recovered, but this cannot be attributed to standard treatment.
Assuntos
Infecções Assintomáticas/terapia , Tratamento Farmacológico da COVID-19 , COVID-19/diagnóstico , Adolescente , Adulto , Idoso , Antibacterianos/uso terapêutico , Antivirais/uso terapêutico , Azitromicina/uso terapêutico , Teste de Ácido Nucleico para COVID-19/métodos , Criança , Pré-Escolar , Quimioterapia Combinada , Feminino , Hospitalização , Humanos , Hidroxicloroquina/uso terapêutico , Lactente , Lopinavir/uso terapêutico , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Ritonavir/uso terapêutico , SARS-CoV-2/isolamento & purificação , Adulto JovemRESUMO
Patients diagnosed with type 2 diabetes mellitus, who then become infected with SARS-CoV-2, are at greater risk of developing complications from COVID-19, which may even lead to death. Diabetes is a chronic condition that requires continuous contact with healthcare facilities; therefore, this type of patients should have regular access to medicines, tests and appointments with healthcare personnel. In Peru, care and treatment continuity have been affected since the national state of emergency due to COVID-19 began; because many healthcare facilities suspended outpatient consultations. The strategies presented in this study were developed by different Peruvian health providers in the pandemic context to ensure care continuity for people with diabetes. This article provides recommendations to strengthen primary healthcare, because it is the first level of healthcare contact for patients with diabetes.
Las personas con diabetes mellitus tipo 2 infectadas por SARS-CoV-2 tienen mayores riesgos de desarrollar COVID-19 con complicaciones y de morir como consecuencia de ella. La diabetes es una condición crónica en la que se requiere continuidad de cuidados que implican un contacto con los establecimientos de salud, pues deben tener acceso regular a medicamentos, exámenes y citas con personal de salud. Esta continuidad de cuidados se ha visto afectada en el Perú a raíz de la declaratoria del estado de emergencia nacional, producto de la pandemia por la COVID-19 pues muchos establecimientos de salud han suspendido las consultas externas. Este artículo describe algunas estrategias que han desarrollado los diferentes proveedores de salud peruanos en el marco de la pandemia para proveer continuidad del cuidado a las personas con diabetes y finalmente brinda recomendaciones para que reciban los cuidados que necesitan a través del fortalecimiento del primer nivel de atención, como el punto de contacto más cercano con las personas con diabetes.
Assuntos
COVID-19/complicações , Continuidade da Assistência ao Paciente/organização & administração , Atenção à Saúde/organização & administração , Diabetes Mellitus Tipo 2/complicações , SARS-CoV-2 , COVID-19/epidemiologia , Diabetes Mellitus Tipo 2/terapia , Emergências/epidemiologia , Acessibilidade aos Serviços de Saúde/organização & administração , Humanos , Programas Nacionais de Saúde , Pandemias , Peru/epidemiologia , TelemedicinaRESUMO
RESUMEN Objetivo: comparar los precios de venta de medicamentos esenciales para el manejo y tratamiento de la COVID-19 en establecimientos farmacéuticos peruanos públicos y privados. Además, estimar el costo por persona del tratamiento farmacológico para casos leves y severos. Materiales y métodos: estudio transversal con información reportada por establecimientos farmacéuticos públicos y privados. El precio de los medicamentos se presenta en medianas y se compararon usando la prueba no paramétrica de Kruskal-Wallis. Además, se estimó el costo por persona y asequibilidad para el tratamiento de casos leves y severos. Resultados: medicamentos para casos leves como azitromicina, hidroxicloquina, ivermectina y paracetamol tienen medianas de precios entre S/ 0,04 (US$ 0,011) y S/ 23,81 (US$ 6,71) en establecimientos públicos, mientras que los mismos medicamentos en establecimientos privados fluctúan entre S/ 1,00 y S/ 36,00. En promedio, los precios de los medicamentos en el sector privado son 11 veces los precios en el sector público. Los costos de tratamiento por persona en establecimientos públicos son más asequibles que en los privados, especialmente para los medicamentos para casos más severos. Los esquemas de tratamiento para casos leves requieren la inversión de entre uno a cuatro días de salario mínimo. Mientras que los tratamientos de casos severos pueden requerir, hasta 64 días de salario mínimo en establecimientos privados. Conclusiones: el tratamiento farmacológico para COVID-19 supone un gasto importante para el sistema de salud público y para las familias a través de gastos de bolsillo. Urge diseñar e implementar medidas regulatorias para mejorar el acceso a medicamentos a precios asequibles.
ABSTRACT Objective: to compare the sale price of essential drugs used in the management and therapy of COVID-19 in public and private pharmacies in Peru. Also, to assess the cost per person of drug therapy for both mild and severe cases. Materials and methods: this is a cross-sectional study using data reported by public and private pharmacies in Peru. Drug prices are presented as median values and they were compared using the non-parametric Kruskal-Wallis test. Also, costs per person and drug accessibility for treating mild and moderate cases were estimated. Results: drugs used when treating mild cases of COVID-19, such as azythromycin, hydroxichloroquine, ivermectin, and paracetamol had median prices between S/ 0.04 (US$ 0.011) and S/ 23.81 (US$ 6.71) in public pharmacies, while the same compounds cost between S/ 1.00 (US$ 0.28) and S/ 36.00 (US$ 10.15) in private pharmacies. On average, drug prices in private pharmacies are 11 times higher compared to those in public pharmacies. Costs for (COVID-19) therapy in public pharmacies are more accessible compared to those found in private pharmacies, particularly for drugs used for more severely affected patients. Therapy regimens for mild cases require spending 1 to 4 days of the minimum daily wages, while therapy for severe cases (of COVID-19) may require up to 64 days of the minimum daily wages in private pharmacies. Conclusions: pharmacological treatment for COVID-19 represents an important expense for the public health system and for families through out-of-pocket expenses. It is urgent to design and implement regulatory measures aiming to improve the access to drug therapy (for Covid-19) in order to have drugs sold at accessible prices.
RESUMO
Objetivo. Evaluar si el nivel de conocimiento sobre la diabetes mellitus 2 (DM2) se asocia con adherencia al tratamiento. Materiales y métodos. Se determinó el nivel de conocimientos sobre la enfermedad en pacientes con DM2 por medio del Diabetes Knowledge Questionnaire (DKQ-24) y se evaluó si existía asociación con adherencia al tratamiento, medida por la prueba de Morisky-Green-Levine (MGL). Se tomó una muestra consecutiva de 210 pacientes. Resultados. El conocimiento sobre DM2 fue considerado adecuado en el 78,1% de los pacientes y se verificó que el 25,7% de ellos estaban adheridos al tratamiento farmacológico. Se halló asociación positiva entre adherencia y conocimientos (OR: 1,12; IC 95%:1,01-1,25) y edad > 65 años (OR: 1,14; IC 95%: 1,03-1,28). Además, se halló una diferencia significativa entre las medias de los puntajes obtenidos entre adherentes versus no adherentes (15,3 vs 16,37; p<0,05). La adherencia al tratamiento de diabetes en nuestro estudio fue de 25%. Conclusiones. Existe asociación de la adherencia al tratamiento con las variables conocimiento adecuado y edad > 65 años. Existen resultados mixtos (no significancia bivariada y sí multivariada) respecto a nivel educativo secundario o superior y procedencia rural de los pacientes; lo que indica que se requieren realizar mayores estudios al respecto.
Objective: To assess whether knowledge about type II diabetes mellitus (T2DM) is associated with adherence to therapy. Materials and Methods: Knowledge about T2DM was assessed by using the Diabetes Knowledge Questionnaire (DKQ-24), and it was determined whether there was an association with adherence to treatment, which was measured using the Morisky-Green-Levine Test (MGL). A consecutive sample including 210 patients was taken. Results: Knowledge about T2DM was considered adequate in 78.1% of patients and it was verified that 25.7% of them were adherent to pharmacological treatment. A positive association between knowledge and adherence was found (OR= 1.12, 95% IC: 1.01-1.25), as well as for age >65 years old (OR: 1.14; 95% IC: 1.03-1.28). Also, a significant difference was found between mean scores obtained when adherent versus non-adherent subjects were compared (15.3 vs. 16.37; p<0.05). Adherence to diabetes treatment in our study was 25%. Conclusions: Factors associated with better adherence to therapy were knowledge level and being more of 65 years old. There are some mixed results (no bivariate significance, presence of multivariate significance) with respect to having gone to high school or college, and for having come from a rural area. Our findings indicate further studies need to be performed.
RESUMO
BACKGROUND: Stroke disproportionately affects people in low-income and middle-income countries. Although improvements in stroke care and outcomes have been reported in high-income countries, little is known about practice and outcomes in low and middle-income countries. We aimed to compare patterns of care available and their association with patient outcomes across countries at different economic levels. METHODS: We studied the patterns and effect of practice variations (ie, treatments used and access to services) among participants in the INTERSTROKE study, an international observational study that enrolled 13â447 stroke patients from 142 clinical sites in 32 countries between Jan 11, 2007, and Aug 8, 2015. We supplemented patient data with a questionnaire about health-care and stroke service facilities at all participating hospitals. Using univariate and multivariate regression analyses to account for patient casemix and service clustering, we estimated the association between services available, treatments given, and patient outcomes (death or dependency) at 1 month. FINDINGS: We obtained full information for 12â342 (92%) of 13â447 INTERSTROKE patients, from 108 hospitals in 28 countries; 2576 from 38 hospitals in ten high-income countries and 9766 from 70 hospitals in 18 low and middle-income countries. Patients in low-income and middle-income countries more often had severe strokes, intracerebral haemorrhage, poorer access to services, and used fewer investigations and treatments (p<0·0001) than those in high-income countries, although only differences in patient characteristics explained the poorer clinical outcomes in low and middle-income countries. However across all countries, irrespective of economic level, access to a stroke unit was associated with improved use of investigations and treatments, access to other rehabilitation services, and improved survival without severe dependency (odds ratio [OR] 1·29; 95% CI 1·14-1·44; all p<0·0001), which was independent of patient casemix characteristics and other measures of care. Use of acute antiplatelet treatment was associated with improved survival (1·39; 1·12-1·72) irrespective of other patient and service characteristics. INTERPRETATION: Evidence-based treatments, diagnostics, and stroke units were less commonly available or used in low and middle-income countries. Access to stroke units and appropriate use of antiplatelet treatment were associated with improved recovery. Improved care and facilities in low-income and middle-income countries are essential to improve outcomes. FUNDING: Chest, Heart and Stroke Scotland.
Assuntos
Padrões de Prática Médica , Acidente Vascular Cerebral/terapia , Idoso , Estudos de Casos e Controles , Países Desenvolvidos , Países em Desenvolvimento , Medicina Baseada em Evidências , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Avaliação de Resultados da Assistência ao Paciente , Pobreza , Inquéritos e Questionários , Análise de Sobrevida , Resultado do TratamentoRESUMO
BACKGROUND: Myocardial injury after noncardiac surgery (MINS) is a mostly asymptomatic condition that is strongly associated with 30-day mortality; however, it remains mostly undetected without systematic troponin T monitoring. We evaluated the cost and consequences of postoperative troponin T monitoring to detect MINS. METHODS: We conducted a model-based cost-consequence analysis to compare the impact of routine troponin T monitoring versus standard care (troponin T measurement triggered by ischemic symptoms) on the incidence of MINS detection. Model inputs were based on Canadian patients enrolled in the Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) study, which enrolled patients aged 45 years or older undergoing inpatient noncardiac surgery. We conducted probability analyses with 10â¯000 iterations and extensive sensitivity analyses. RESULTS: The data were based on 6021 patients (48% men, mean age 65 [standard deviation 12] yr). The 30-day mortality rate for MINS was 9.6%. We determined the incremental cost to avoid missing a MINS event as $1632 (2015 Canadian dollars). The cost-effectiveness of troponin monitoring was higher in patient subgroups at higher risk for MINS, e.g., those aged 65 years or more, or with a history of atherosclerosis or diabetes ($1309). CONCLUSION: The costs associated with a troponin T monitoring program to detect MINS were moderate. Based on the estimated incremental cost per health gain, implementation of postoperative troponin T monitoring seems appealing, particularly in patients at high risk for MINS.
CONTEXTE: Les lésions myocardiques après chirurgie non cardiaque (CNC) sont majoritairement asymptomatiques et fortement associées au risque de mortalité dans les 30 jours; toutefois, dans la plupart des cas, elles ne sont pas détectées en l'absence d'une surveillance systématique de la troponine T. Nous avons évalué les coûts et les conséquences d'une telle surveillance pour détecter les lésions myocardiques après CNC. MÉTHODES: Nous avons mené une analyse coût-conséquence modélisée pour comparer la surveillance systématique de la troponine T aux soins habituels seuls (mesure de la troponine T seulement s'il y a présence de symptômes d'ischémie) sur la fréquence de détection de lésions myocardiques après CNC. Les données ayant servi à l'analyse provenaient des patients canadiens ayant participé à l'étude de cohorte VISION, qui visait à évaluer les complications vasculaires chez les patients de 45 ans et plus ayant subi une CNC. Nous avons mené des analyses de probabilité avec 10 â¯000 itérations et des analyses de sensibilité approfondies. RÉSULTATS: Les données portaient sur 6021 patients (48â¯% du sexe masculin; âge moyen de 65 ans [écart-type de 12 ans]). Le taux de mortalité dans les 30 jours associé à une lésion myocardique après CNC était de 9,6â¯%. Nous avons déterminé que le coût marginal de la détection de la présence d'une lésion par surveillance de la troponine T était de 1632â¯$ (dollars canadiens en 2015). Le rapport coût-efficacité était plus bas pour les sous-groupes de patients à risque élevé de lésion myocardique après CNC, comme les patients de 65 ans et plus ou ceux ayant des antécédents d'athérosclérose ou de diabète (1309â¯$), que pour leurs pairs. CONCLUSION: Les coûts associés à un programme de surveillance de la troponine T pour détecter les lésions myocardiques après CNC étaient modérés. Le coût marginal estimé par gain de santé indique que la mise en Åuvre de ce type de programme pourrait être une option intéressante, surtout pour les patients à risque élevé de lésion myocardique après CNC.
Assuntos
Análise Custo-Benefício , Isquemia Miocárdica , Avaliação de Resultados em Cuidados de Saúde , Cuidados Pós-Operatórios , Complicações Pós-Operatórias , Procedimentos Cirúrgicos Operatórios/efeitos adversos , Troponina T/sangue , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/sangue , Isquemia Miocárdica/diagnóstico , Isquemia Miocárdica/economia , Isquemia Miocárdica/mortalidade , Avaliação de Resultados em Cuidados de Saúde/economia , Cuidados Pós-Operatórios/economia , Cuidados Pós-Operatórios/métodos , Cuidados Pós-Operatórios/normas , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/economia , Complicações Pós-Operatórias/mortalidade , RiscoRESUMO
BACKGROUND: Childhood obesity is emerging as a major public health problem worldwide. To date, most studies of obesity and overweight in Peru are focused on adults, with few of them involving children, a population at a critical stage of development. The trend in overweight and obesity prevalence in Peruvian children under the age of five has not yet been determined. Thus, the objective of the present study is to evaluate the prevalence rates of overweight and obesity between 2010 and 2015 in children under the age of five, stratified by geographical areas in Peru. METHODS: Data were obtained from the Nutritional Status Information System of Peru. The total number of children evaluated was 14,155,914. For the Geographic Information Systems (GIS), the program Geo Da 1.8® was used to ascertain the spatial distribution of prevalence rates and was mapped for children under five. To assess the degree of spatial dependence, exploratory spatial data analysis was performed using the Moran's I statistic and was assessed with the Local Indicators of Spatial Association (LISA) analysis to identify geographic concentrations of high and low of obesity and overweight levels. RESULTS: Between 2010 and 2015, the national prevalence of childhood overweight and obesity ranged from 6.2%- 6.8% and 1.5%-2.7%, respectively. The highest prevalence of childhood overweight and obesity was found in 2014 and 2013, respectively. During these years, we observed that obesity decreased, but overweight remained stable. The highest prevalence of overweight and obesity was found in the departments located on the coast. Significant positive spatial autocorrelation was found for both overweight and obesity. The departments with the highest prevalence of overweight and obesity were concentrated in Lima, Callao, Ica, Moquegua and Tacna. The lowest were found in Loreto, Cusco and San Martin. CONCLUSION: The decrease in obesity and the stabilisation of overweight are positive results for the Peruvian childhood. However, in comparison with other Latin American countries, Peru still lags in obesity prevention.
Assuntos
Disparidades nos Níveis de Saúde , Obesidade Infantil/epidemiologia , Pré-Escolar , Geografia , Humanos , Lactente , Peru/epidemiologia , Prevalência , Análise EspacialRESUMO
The CRONICAS Centre of Excellence in Chronic Diseases, based at Universidad Peruana Cayetano Heredia, was created in 2009 with support from the U.S. National Heart, Lung, and Blood Institute (NHLBI). The vision of CRONICAS is to build a globally recognized center of excellence conducting quality and innovative research and generating high-impact evidence for health. The center's identity is embedded in its core values: generosity, innovation, integrity, and quality. This review has been structured to describe the development of the CRONICAS Centre, with a focus on highlighting the ongoing translational research projects and capacity-building strategies. The CRONICAS Centre of Excellence is not a risk-averse organization: it benefits from past experiences, including past mistakes, and improves upon them and thus challenges traditional research approaches. This ethos and environment are key to fostering innovation in research.
Assuntos
Academias e Institutos/organização & administração , Doença Crônica , Pesquisa Translacional Biomédica/organização & administração , Saúde Global , Humanos , National Heart, Lung, and Blood Institute (U.S.) , Objetivos Organizacionais , Peru , Desenvolvimento de Programas , Apoio à Pesquisa como Assunto , Estados UnidosRESUMO
BACKGROUND: The interaction between physicians and the pharmaceutical industry influences physicians' attitudes and prescribing behavior. Although largely studied in the US, this topic has not been well studied in resource-poor settings, where a close relationship between physicians and industry still exists. OBJECTIVE: To describe physician interactions with and attitudes towards the pharmaceutical industry in a public general hospital in Lima, Peru. DESIGN: Descriptive, cross-sectional study through an anonymous, self-filled questionnaire distributed among faculty and trainee physicians of five different clinical departments working in a Peruvian public general hospital. A transcultural validation of an existing Spanish questionnaire was performed. Exposure to marketing activities, motivations to contact pharmaceutical representatives and attitudes towards industry were studied. Collected data was analyzed by degree of training, clinical department, gender and teaching status. Attitudes were measured on a four-point LIKERT scale. RESULTS: 155 physicians completed the survey, of which 148 were included in the study sample. 94.5% of attending physicians reported ongoing encounters with pharmaceutical representatives. The most common industry-related activities were receiving medical samples (91.2%), promotional material (87.8%) and attending meetings in restaurants (81.8%). Respondents considered medical samples and continuing medical education the most ethically acceptable benefits. We found significant differences between attendings and residents, and teaching and non-teaching attendings. An association between the amount of encounters with pharmaceutical representatives, and attitudes towards industry and acceptance of medical samples was found. CONCLUSIONS: A close physician-industry relationship exists in the population under study. The contact is established mainly through pharmaceutical representatives. Medical samples are the most received and ethically accepted benefit. The attitudes of physicians on the ethical standards of acceptance of medical samples and other benefits are closely related with their exposure to the pharmaceutical industry. Future studies could explore the motivations of physicians working in resource-poor settings to maintain a close relationship with industry.
Assuntos
Atitude do Pessoal de Saúde , Ética Médica , Hospitais Públicos/ética , Relações Interprofissionais/ética , Médicos/ética , Padrões de Prática Médica/ética , Adulto , Conflito de Interesses , Estudos Transversais , Indústria Farmacêutica/economia , Indústria Farmacêutica/ética , Feminino , Doações/ética , Hospitais Gerais , Humanos , Masculino , Marketing/ética , Pessoa de Meia-Idade , Peru , Médicos/economia , Padrões de Prática Médica/economia , Inquéritos e QuestionáriosRESUMO
El modelo de atención en salud paternalista está derivando hacia modelos más participativos, como lo es la toma de decisiones compartidas (TDC), en el que se considera al paciente como agente responsable y autónomo. La TDC representa un enfoque terapéutico en el que profesionales y pacientes comparten la mejor evidencia científica disponible para tomar una decisión, incorporando los valores y preferencias del paciente. Este intercambio de información puede facilitarse mediante el uso de herramientas de ayuda para la TDC, que han demostrado ser efectivas para mejorar el conocimiento, la satisfacción del paciente, y reducir el conflicto decisional. En este sentido, las habilidades comunicacionales ejercen un rol fundamental en el establecimiento de la relación profesional - paciente, facilitando el intercambio de información y preferencias de manera efectiva y respetuosa. Esta aproximación terapéutica podría apoyar la reducción de las disparidades en salud que prevalecen en Latinoamérica, al facilitar que las personas puedan participar informada y activamente en el cuidado de su salud.
The healthcare model is shifting from a paternalistic towards a more inclusive and participative approach, such as shared decision making (SDM). SDM considers patients as autonomous and responsible agents. SDM is a therapeutic approach where healthcare providers and patients share the best evidence available to make a decision according to the values and preferences of the patient. Decision aids are tools that can facilitate this information exchange. These tools help patients to increase knowledge about options, reduce decisional conflict and improve satisfaction. Additionally, communication skills play a key role within the professional-patient relationship, as they facilitate sharing information and preferences in an effective and respectful manner. This therapeutic approach could support the reduction of health inequalities that affect Latin America, as it promotes an active and informed participation of patients in their healthcare process.
Assuntos
Humanos , Tomada de Decisões , Atenção à Saúde/métodos , Participação do Paciente , Relações Médico-PacienteRESUMO
BACKGROUND: Little is known about the extent to which Peruvian physicians seek to involve patients in shared decision making, or about the variation in these efforts across different settings. OBJECTIVE: To measure the extent to which Peruvian clinicians involve their patients in decision making and to explore the differences between clinicians' behavior in private vs. public practice. DESIGN: Videographic analysis. PARTICIPANTS AND SETTING: Seven academic physicians who provided care to patients in a public and a private setting participate in this study. All the encounters in both settings were filmed on one random day of February 2012. APPROACH: Two raters, working independently and in duplicate used the 12-item OPTION scale to quantify the extent of physician effort to involve patients in shared decision making (with 0 indicating no effort and 100 maximum possible effort) in 58 video recordings of usual clinical encounters in private and public practice. RESULTS: The mean OPTION score was 14.3 (SD 7.0). Although the OPTION score in the private setting (mean 16.5, SD 7.3) was higher than in the public setting (mean 12.3 SD 6.1) this difference was not statistically significant (p = .09). CONCLUSION: Peruvian academic physicians in this convenience sample barely sought to involve their patients in shared decision making. Additional studies are required to confirm these results which suggest that patient-centered care remains an unfulfilled promise and a source of inequity within and across the private and the public sectors in Peru.
Assuntos
Tomada de Decisões , Instalações de Saúde , Relações Médico-Paciente , Adulto , Idoso , Atitude do Pessoal de Saúde , Comunicação , Atenção à Saúde , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Participação do Paciente , Assistência Centrada no Paciente , Peru , Médicos , Reprodutibilidade dos Testes , Gravação em VídeoRESUMO
The healthcare model is shifting from a paternalistic towards a more inclusive and participative approach, such as shared decision making (SDM). SDM considers patients as autonomous and responsible agents. SDM is a therapeutic approach where healthcare providers and patients share the best evidence available to make a decision according to the values and preferences of the patient. Decision aids are tools that can facilitate this information exchange. These tools help patients to increase knowledge about options, reduce decisional conflict and improve satisfaction. Additionally, communication skills play a key role within the professional-patient relationship, as they facilitate sharing information and preferences in an effective and respectful manner. This therapeutic approach could support the reduction of health inequalities that affect Latin America, as it promotes an active and informed participation of patients in their healthcare process.
Assuntos
Tomada de Decisões , Atenção à Saúde/métodos , Participação do Paciente , Humanos , Relações Médico-PacienteRESUMO
La participación del Instituto Nacional de Salud como ente rector en la evaluación ética, metodológica y, por consiguiente, a cargo de la aprobación de la ejecución de estudios, data del año 1995. Desde entonces ha existido un gran incremento de ensayos clínicos hasta el 2009, por lo que se realizó un análisis preliminar para evaluar si este incremento ha repercutido en la producción de ensayos clínicos sobre tópicos endémicos o problemas de carga de enfermedad que deben ser investigados y resueltos por los peruanos. Para ello, se realizó una búsqueda en SCOPUS Y MEDLINE, pudiendo identificar 102 ensayos clínicos en humanos, diseñados, ejecutados y realizados en el Perú sobre problemas endémicos o propios del Perú. La apreciación en el tiempo no permite afirmar que haya ocurrido un incremento en paralelo, ni que se hayan incluido a nuevos grupos de investigación o nuevos investigadores, no se investiga sobre problemas endémicos de nuestro país, no se ha realizado por ejemplo ningún ensayo clínico sobre la enfermedad de Carrión, son muy pocos los ensayos clínicos promovidos durante este tiempo por instituciones académicas y de la sociedad civil. Teniendo en cuenta ello, podemos afirmar que no se aprecia una influencia positiva en la generación de ensayos clínicos autóctonos, sobre problemas locales que a los peruanos les corresponde resolver.
The participation of the National Institute of Health as a leader in ethical and methodological assessment and its responsibility to approve the implementation of studies dates back to 1995. Since then, clinical trials have increased significantly until 2009; for this reason, a preliminary analysis was made to assess whether this increase has had an impact in the production of clinical trials on endemic topics or disease burden problems that must be researched and resolved by Peruvian people. For this purpose, a search in SCOPUS and MEDLINE was conducted, with 102 clinical trials in humans found, all of them designed, implemented and carried out in Peru on endemic or domestic health issues. Observation over time does not reveal any parallel increase or the inclusion of new research groups or researchers, no research on endemic problems has been carried out in our country; for example, clinical trials on the Carrions Disease have not been conducted. Very few clinical trials have been promoted during this period by academic institutions and the civil society. Taking this into consideration, we can affirm that there is no positive influence in the generation of native clinical trials on local problems that Peruvian people need to resolve.
Assuntos
Humanos , Pesquisa Biomédica , Ensaios Clínicos como Assunto , Pesquisa Biomédica/métodos , PeruRESUMO
Synthesis studies (SS): systematic review and meta-analysis are the basis for developing Health Economic Evaluations (HEE). SS allow us to obtain parameters for estimating probabilities and effectiveness from the combination of the results of primary studies, and, as they include in their methodology the selection, evaluation, systematization and synthesis processes, they are considered the first level of hierarchy in scientific evidence. Nevertheless, they can be prone to bias and methodological failures that can affect the validity of their results. This article initially presents the relevance of the randomization in the hierarchic classification of research designs, then it reviews the main factors affecting the validity of the SS, emphasising the publication bias, the heterogeneity and the inclusion of primary studies with main objective differing from the one of the SS. Moreover, it presents individual studies like a valid alternative for the development of a SS. The conclusion is that one of the key aspects in a SS is the correct evaluation of the study types and the objective evaluation of their quality, being these primary or secondary.
Assuntos
Estudos de Avaliação como Assunto , Custos de Cuidados de Saúde , Metanálise como Assunto , Viés de Publicação , Literatura de Revisão como AssuntoRESUMO
Los estudios de síntesis (EDS): revisiones sistemáticas y metanálisis, son base para llevar a cabo las evaluaciones económicas en salud (EES). Los EDS, al permitir obtener parámetros para las probabilidades de estimación y de efectividad a partir de la combinación de resultados de estudios primarios y, al incluir en su metodología procesos de selección, evaluación, sistematización y síntesis, son considerados como el primer nivel de jerarquía en la evidencia científica. No obstante, pueden estar sometidos a sesgos y fallas metodológicas que afectan su validez. El presente artículo expone, inicialmente, la importancia de la aleatorización en la jerarquización de los diseños de investigación; luego se revisa los principales factores que afectan la validez de los EDS, incidiendo en el sesgo de publicación, la heterogeneidad y la inclusión de estudios primarios con objetivos principales distintos al del EDS; asimismo, se presenta a los estudios individuales como una alternativa válida para el desarrollo de una EES. Se concluye que uno de los aspectos claves en una EES es la selección adecuada de los tipos de estudio, sean estos primarios o secundarios.
Synthesis studies (SS): systematic review and meta-analysis are the basis for developing Health Economic Evaluations (HEE). SS allow us to obtain parameters for estimating probabilities and effectiveness from the combination of the results of primary studies, and, as they include in their methodology the selection, evaluation, systematization and synthesis processes, they are considered the first level of hierarchy in scientific evidence. Nevertheless, they can be prone to bias and methodological failures that can affect the validity of their results. This article initially presents the relevance of the randomization in the hierarchic classification of research designs, then it reviews the main factors affecting the validity of the SS, emphasising the publication bias, the heterogeneity and the inclusion of primary studies with main objective differing from the one of the SS. Moreover, it presents individual studies like a valid alternative for the development of a SS. The conclusion is that one of the key aspects in a SS is the correct evaluation of the study types and the objective evaluation of their quality, being these primary or secondary.
Assuntos
Estudos de Avaliação como Assunto , Custos de Cuidados de Saúde , Metanálise como Assunto , Viés de Publicação , Literatura de Revisão como AssuntoRESUMO
OBJECTIVE: To assist investigators planning, coordinating, and conducting systematic reviews in the selection of data-extraction tools for conducting systematic reviews. STUDY DESIGN AND SETTING: We constructed an initial table listing available data-collection tools and reflecting our experience with these tools and their performance. An international group of experts iteratively reviewed the table and reflected on the performance of the tools until no new insights and consensus resulted. RESULTS: Several tools are available to manage data in systematic reviews, including paper and pencil, spreadsheets, web-based surveys, electronic databases, and web-based specialized software. Each tool offers benefits and drawbacks: specialized web-based software is well suited in most ways, but is associated with higher setup costs. Other approaches vary in their setup costs and difficulty, training requirements, portability and accessibility, versatility, progress tracking, and the ability to manage, present, store, and retrieve data. CONCLUSION: Available funding, number and location of reviewers, data needs, and the complexity of the project should govern the selection of a data-extraction tool when conducting systematic reviews.